185 related articles for article (PubMed ID: 28418595)
1. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.
Kim MN; Hwang SG; Rim KS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
Liver Int; 2017 Dec; 37(12):1788-1795. PubMed ID: 28418595
[TBL] [Abstract][Full Text] [Related]
2. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
3. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Papatheodoridis GV; Dalekos GN; Yurdaydin C; Buti M; Goulis J; Arends P; Sypsa V; Manolakopoulos S; Mangia G; Gatselis N; Keskın O; Savvidou S; Hansen BE; Papaioannou C; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2015 Feb; 62(2):363-70. PubMed ID: 25195548
[TBL] [Abstract][Full Text] [Related]
5. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
6. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
7. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.
Lee HW; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Liver Int; 2019 Sep; 39(9):1624-1630. PubMed ID: 31050379
[TBL] [Abstract][Full Text] [Related]
8. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Kim HY; Lampertico P; Nam JY; Lee HC; Kim SU; Sinn DH; Seo YS; Lee HA; Park SY; Lim YS; Jang ES; Yoon EL; Kim HS; Kim SE; Ahn SB; Shim JJ; Jeong SW; Jung YJ; Sohn JH; Cho YK; Jun DW; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen HLA; Jang MJ; Lee YB; Kim YJ; Yoon JH; Papatheodoridis GV; Lee JH
J Hepatol; 2022 Feb; 76(2):311-318. PubMed ID: 34606915
[TBL] [Abstract][Full Text] [Related]
9. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
[TBL] [Abstract][Full Text] [Related]
10. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
11. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
12. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
[TBL] [Abstract][Full Text] [Related]
13. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
15. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
17. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
[TBL] [Abstract][Full Text] [Related]
18. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Arends P; Sonneveld MJ; Zoutendijk R; Carey I; Brown A; Fasano M; Mutimer D; Deterding K; Reijnders JG; Oo Y; Petersen J; van Bömmel F; de Knegt RJ; Santantonio T; Berg T; Welzel TM; Wedemeyer H; Buti M; Pradat P; Zoulim F; Hansen B; Janssen HL;
Gut; 2015 Aug; 64(8):1289-95. PubMed ID: 25011935
[TBL] [Abstract][Full Text] [Related]
19. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
20. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
